We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

EUROIMMUN AG

EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App




Autoantibody Status Guides Treatment in Myasthenia Gravis

By LabMedica International staff writers
Posted on 20 Dec 2023
Print article
Image: Autoantibody status plays an important role in the diagnosis and therapy of myasthenia gravis (Photo courtesy of EUROIMMUN)
Image: Autoantibody status plays an important role in the diagnosis and therapy of myasthenia gravis (Photo courtesy of EUROIMMUN)

Autoantibody status plays a significant role in diagnosis and therapy decisions for myasthenia gravis (MG), an immune-mediated neuromuscular junction disorder. The key serological markers in MG are antibodies against nicotinic acetylcholine receptors (AChR), which are found in about 85% of cases, and antibodies against muscle-specific kinase (MuSK), which are observed in approximately 6% of cases, the majority of which are anti-AChR negative. 15% of MG cases are seronegative. The antibody-mediated processes in MG result in the loss of functional AChR at the motor endplate, either through direct blocking, antigen modulation, or complement-mediated damage of the muscle membranes. Anti-AChR antibodies belong to the IgG1 subclass and can activate the complement cascade. In AChR antibody-positive cases, complement-inhibiting drugs are among the recommended therapies. On the other hand, anti-MuSK antibodies belong to the non-complement binding IgG4 subclass, as a result of which complement inhibitors are ineffective for this form. Hence, therapy selection should consider the autoantibody status along with disease activity, thymus pathology, and the patient’s age.

Currently, the gold standard for detection of anti-AChR and MuSK antibodies is radioimmunoprecipitation assay (RIPA) although it comes with a disadvantage of the need for radioactive reagents. Cell-based indirect immunofluorescence assays (CBAs) offer a viable alternative that is easier to implement. EUROIMMUN (Lübeck, Germany) has developed CBAs based on transfected human cell lines expressing the corresponding target antigens AChR (adult: AChR-E and fetal: AChR-G) and MuSK. In an evaluation study published in the Journal of the Neurological Sciences, the EUROIMMUN Anti-AChR CBA demonstrated similarly excellent specificity and a significantly higher sensitivity for MG compared to RIPA, detecting anti-AChR in 21% of patients otherwise considered to be seronegative.

In a further analysis, the Anti-AChR and Anti-MuSK CBAs demonstrated high positive and 100% negative agreement with RIPA in patients with clinically confirmed MG. CBAs thus provide equivalent or superior performance to RIPA without the use of radioactive materials. Moreover, anti-AChR and anti-MuSK antibodies can be analyzed simultaneously using the EUROIMMUN Myasthenia gravis Mosaic 2, which provides a composite of CBAs for adult/fetal AChR and MuSK together with a control substrate. This test is currently the only commercially available multiparameter assay for anti-AChR and anti-MuSK. The CBAs are CE-marked. The CBA procedure is simple and can be performed in any laboratory familiar with indirect immunofluorescence. There are automation options available to aid the processing and evaluation, allowing for the assay’s smooth integration into laboratory routines.

Related Links:
EUROIMMUN

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Myeloperoxidase Assay
IDK MPO ELISA

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.